Latest news with #Geiger
Business Insider
23-07-2025
- Business
- Business Insider
Chipotle Mexican Grill (CMG) Is About to Report Q2 Earnings. Here's What to Expect
Chipotle Mexican Grill (CMG) is scheduled to announce its results for the second quarter on Wednesday, July 23. CMG stock is down 13% year-to-date, as investors are concerned about the impact of a slowdown in consumer spending and inflation on the Mexican restaurant chain's performance. Wall Street expects Chipotle to report earnings per share (EPS) of $0.33, indicating a 2.9% year-over-year decline. Meanwhile, revenue is expected to rise about 5% to $3.11 billion. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Investors will pay attention to management's commentary on the demand backdrop and the impact of tariffs. The company reported mixed results for the first quarter, citing a slowdown in consumer spending and unfavorable weather. As seen in this chart from Main Street Data, CMG's restaurant-level operating margin contracted to 26.2% in Q1 2025 from 27.5% in the prior-year quarter. This decline was due to higher input costs and increased labor expenses. Analysts' Views Ahead of CMG's Q2 Earnings Ahead of the Q2 results, UBS analyst Dennis Geiger increased the price target for Chipotle Mexican Grill stock to $65 from $60 and reaffirmed a Buy rating. The 4-star analyst expects CMG's same-store sales in the second half of 2025 to improve following a challenging first half. Geiger anticipates that Chipotle's Q2 results will reflect pressured sales due to macroeconomic challenges and tough comparisons. That said, the analyst expects the underlying trends to improve through the quarter, with initiatives in place to support a positive sales and traffic inflection in the second half of 2025. Geiger expects the company to keep its full-year guidance largely unchanged. Overall, the analyst believes that Chipotle remains well-positioned to deliver positive transaction growth and mid-single-digit same-store growth over the long term, with potential for margin expansion and accelerating unit development to support a 20% EPS growth. He views CMG as one of the 'highest quality' growth stocks in the sector. Likewise, KeyBanc analyst Eric Gonzalez raised the price target for CMG stock to $60 from $58 and reaffirmed a Buy rating. The 4-star analyst believes that sentiment 'skews most positively' on YUM! Brands (YUM) and Shake Shack (SHAK), while investors seem to be 'warming up' to Chipotle and McDonald's (MCD) more than they have in the past few months, as these two companies are expected to fare better in July than they did during the second quarter. Gonzalez increased the price target for CMG stock to reflect improving same-store sales trends in the second half of the year. While the analyst expects CMG to slightly lag the Street's Q2 same-store sales estimate, he noted that KeyBanc's data suggests improved sales trends in recent weeks, which makes the Q3 2025 same-store sales growth estimate of 2.0% seem conservative. Given aggressive menu innovation in the second half and 'undemanding' year-over-year comparisons, Gonzalez is optimistic that CMG will exit 2025 with solid momentum. AI Analyst Is Bullish on Chipotle Stock Ahead of Q2 Print TipRanks' AI stock analysis reflects an Outperform rating on Chipotle stock with a price target of $61, reflecting a 16.3% upside potential. The AI analyst rating is based on strong financial performance and cash flow management. However, technical analysis reveals mixed signals, and valuation looks elevated. Here's What Options Traders Anticipate Ahead of CMG's Q2 Earnings Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry, the Options tool does this for you. Indeed, it currently says that options traders are expecting about a 7.07% move in either direction in Chipotle stock in reaction to Q2 results. Is CMG Stock a Buy or Sell? Currently, Wall Street has a Moderate Buy consensus rating on Chipotle Mexican Grill stock based on 21 Buys and eight Hold recommendations. The average CMG stock price target of $60.44 indicates 15.2% upside potential from current levels.
Cision Canada
08-07-2025
- Health
- Cision Canada
Saskatchewan Entrepreneurs Launch Addiction Recovery App on iOS and Android
, July 8, 2025 /CNW/ - A Saskatchewan-born tech startup is redefining how we think about addiction, mental health, and the human experience. Founded by a team with lived experience in both addiction and recovery, AlchemistOne is now available for download on iOS and Android. The app offers a powerful digital companion for those navigating addiction, anxiety, depression, and the often-overlooked complexity of the mind itself. Developed in Regina, with operations spanning Saskatchewan and Alberta, AlchemistOne delivers deeply personalized experiences rooted in mindfulness, introspection, and self-inquiry. Its content is curated by mental health professionals and individuals in long-term recovery from around the world, offering profound insight into what it means to struggle, what it means to think, and how freedom can arise from a healthier relationship with our inner world. "When we're struggling, there can be a prevailing sense that we're broken, or not good enough, or that we don't fit in," said Adam Geiger, Co-Founder and CEO of AlchemistOne. "Freedom comes in discovering that's simply not true." Key features of AlchemistOne include: A growing library of personalized audio and video journeys — from guided meditations to raw, honest reflections by recovering addicts, therapists, and philosophers. In-app workout tracking and integration with wearables. Integrated Quests that encourage deeper reflection through journaling, gratitude practices, and other self-guided activities. Coming soon: AlchemistOne's AI-powered support tool, co-designed with people in recovery and mental health professionals. At the heart of the platform is a lived-experience model that challenges conventional narratives around mental health, offering not just coping strategies, but a reimagined way of relating to ourselves. "AlchemistOne is built on the real experiences of people who've been there, including myself," said Geiger. "Addiction and depression can feel incredibly isolating and overwhelming. Our goal is to ensure no one has to face it alone, and to provide hope that there really is another way." With addiction and mental health challenges continuing to rise across Canada and globally, many are turning to new tools and approaches for support. "Technology alone isn't the answer," said Geiger. "But it can be a powerful ally - especially when it's built by and for people in recovery. We're grateful for the opportunity to offer a possible solution." About AlchemistOne AlchemistOne is a mental health and addiction recovery platform designed to help people reframe their relationship with the mind. The app combines evidence-informed tools, community-driven content, and soon, AI-assisted support — all grounded in lived experience — to empower individuals seeking freedom from addiction. SOURCE AlchemistOne Inc.
Business Insider
02-07-2025
- Business
- Business Insider
MCD vs. TXRH vs. CAVA: Which Restaurant Stock Has the Highest Upside Potential?
Macro uncertainties and tariff-led pressure on costs are expected to continue to weigh on the performance of restaurant chains. While ongoing headwinds could impact restaurant stocks over the near term, analysts remain optimistic about the long-term growth prospects of several restaurant stocks. Using TipRanks' Stock Comparison Tool, we placed McDonald's (MCD), Texas Roadhouse (TXRH), and CAVA Group (CAVA) against each other to find the restaurant stock that has the highest upside potential, according to Wall Street. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. McDonald's (NYSE:MCD) Stock McDonald's stock has risen about 15% over the past year, but is essentially flat on a year-to-date basis. The fast-food chain reported mixed results for the first quarter of 2025, largely due to a challenging macroeconomic backdrop. In fact, U.S. same-store sales fell for the second straight quarter, posting the largest decline (down 3.6% in Q1 2025) since the onset of the COVID-19 pandemic. Unfavorable weather and cautious consumer spending impacted McDonald's sales in the first quarter. Nonetheless, McDonald's reaffirmed its full-year guidance, reflecting resilience in a tough backdrop. The company stated that it is working on improving its performance by focusing on value meals, menu innovation, and product launches such as McCrispy Chicken Strips and the reintroduction of snack wraps. Is McDonald's Stock a Buy, Sell, or Hold? Last week, UBS analyst Dennis Geiger reiterated a Buy rating on McDonald's stock with a price target of $350. The 4-star analyst believes that the pullback in the stock, combined with encouraging U.S. sales in the second half of 2025, makes MCD an attractive pick. The analyst sees a 'reasonably limited' downside in MCD stock, as he believes that it is a quality business positioned for multi-year market share gains. While Geiger agreed that consumer defensives are out of favor and quick service restaurant (QSR) sales trends and stocks continue to be under pressure, he expects to see share gains as U.S. and International trends improve. He added that McDonald's appears well-positioned to deliver strong same-store sales in the second half of 2025, driven by new products, value initiatives, and marketing plans, even as lower and middle-income spending pressure could persist. Currently, Wall Street has a Moderate Buy consensus rating on McDonald's stock based on 12 Buys, 13 Holds, and one Sell recommendation. The average MCD stock price target of $329.42 indicates about 13% upside potential. See more MCD analyst ratings Texas Roadhouse (NASDAQ:TXRH) Stock Texas Roadhouse is a casual dining steakhouse chain. The company missed analysts' earnings expectations for the first quarter of Fiscal 2025, as restaurant margins contracted due to commodity inflation and increased wages and other labor expenses. TXRH's comparable restaurant sales increased by 3.5% in Q1 2025. The company indicated that trends were improving, with comparable restaurant sales rising 5% in the first five weeks of Q2 FY25. Additionally, Texas Roadhouse increased its menu prices by about 1.4% in early April. Is TXRH a Good Stock to Buy? Recently, Texas Roadhouse announced the departure of CFO Chris Monroe from the company and the appointment of Vice President of Finance Keith Humpich as the interim CFO. Reacting to the news, Stephens analyst Jim Salera stated that the interim CFO appointment adds stability following Monroe's departure, given Humpich's long tenure and familiarity with the company's financial operations. Salera added that Texas Roadhouse continues to outperform casual dining rivals, with April traffic accelerating exiting Q1 2025. The analyst believes that the company's consistent execution, guest focus, and 'scratch-made' menu continue to be key differentiators in an uncertain consumer backdrop. However, Salera maintained a Hold rating on TXRH stock with a price target of $170, citing concerns related to macro uncertainty in the second half of 2025 and a premium valuation. Overall, Texas Roadhouse stock scores a Moderate Buy consensus rating based on seven Buys and nine Holds. The average TXRH stock price target of $190.87 indicates a modest upside potential of about 2% from current levels. TXRH stock has risen 9% over the past year. Cava Group (NYSE:CAVA) Stock Mediterranean fast casual restaurant chain Cava Group delivered better-than-expected earnings for the first quarter of 2025, with revenue growing 28% to $332 million. The company's same-store sales increased by 10.8%, outperforming several peers in the industry. Despite the strong results, CAVA stock has declined 25% year-to-date and 9% over the past year owing to concerns over valuation and macro uncertainties. Looking ahead, management aims to capitalize on ample opportunities to expand. The company expects to open 64 to 68 new restaurants this year, a slight increase from the previous forecast of 62 to 66 stores. Cava Group operated 382 restaurants as of the end of Q1 2025 and aims to increase its footprint to at least 1,000 restaurants by 2032. Is CAVA Stock a Buy? Recently, Stifel analyst Chris O'Cull reiterated a Buy rating on Cava Group stock but lowered the price target to $125 from $175. The 5-star analyst sees the pullback in the stock as a buying opportunity. Despite near-term challenges, the analyst believes that McDonald's long-term outlook is intact, supported by unit expansion, increasing brand awareness, and improving average unit volumes. He expects McDonald's long-term revenue growth in the 17% to 20% range, driven by a 15% unit growth and mid-single-digit same-restaurant sales (SRS) gains. O'Cull acknowledged near-term softness in CAVA's SRS growth, particularly in the second quarter, due to tough comparisons with the prior-year quarter, which included the launch of the popular Grilled Steak. The analyst now expects Q2 SRS of 5.5%, below the Street's estimate of 6.9%. That said, he noted the strength in CAVA's fundamentals, calling the dip in the stock 'a dish worth grabbing.' O'Cull expects Cava Group's average unit volumes (AUVs) to grow faster than previously expected, fueled by brand expansion and improved performance at new locations. He expects the company's EBIT margin to improve to the range of 9% to 10% by 2030 from an estimated 4.8% in Fiscal 2025, driven by scale efficiencies. CAVA stock price target of $112.92 indicates 34% upside potential. Conclusion Currently, Wall Street is cautiously optimistic about all three restaurant stocks discussed above. Currently, they see higher upside potential in CAVA stock than in MCD and TXRH stocks. Analysts view the pullback in CAVA stock as an attractive buying opportunity to build a position and gain from the company's long-term growth potential.
Yahoo
23-05-2025
- Health
- Yahoo
Man Tries to Save Snake Not Knowing It Was Venomous. He Spent 2 Nights in the Hospital After Getting Bitten
New York City writer Dan Geiger tried to save a snake he spotted while cycling in New Jersey Although he didn't know it at the time, the snake was venomous — and ended up biting him In images shared by Hackensack University Medical Center, where he had to stay for two nights to recover, the writer's finger was captured with a swollen black woundA man tried to help move a snake out of the road and got a nasty bite in the process. Dan Deiger was cycling in New Jersey's Palisades Cliffs on Wednesday, May 21, when he saw a small snake, according to a Hackensack Memorial Health press release. Not wanting the serpent to be injured by a bike, the writer — who lives in New York City — decided he was going to help move the creature away. However, unbeknownst to him, it was a venomous Copperhead. 'He first tried nudging the snake with his water bottle, hoping it would slither away,' the hospital wrote. 'When it didn't budge, Dan made a split-second decision he now regrets. He reached out with his hand. In a flash, the snake struck, sinking its fangs into his finger.' "Dan immediately knew something was wrong. Although he didn't know what type of snake it was, he assumed based on how much he was bleeding, it was venomous," the hospital continued. Fortunately, he was able to flag down two strangers to call 911. Geiger told local Fox affiliate WNYW that ultimately, his 'hand was just too close to its head." "It struck me with precision and speed," he added. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories. While it's rare for someone to die from a Copperhead snake's venom, a limb can be seriously damaged as a result of the bite, according to Hackensack Memorial Health. 'It contains toxins that break down tissue, causing intense pain, swelling, blistering, and even tissue death (necrosis),' they explained. The venom also disrupts blood clotting, leading to internal bleeding and further complications. The longer the venom circulates, the more widespread the damage.' In pictures shared by Hackensack Memorial Health, the snake bite victim's index finger featured a swollen, black wound. According to the hospital, Geiger stayed there for two nights before being discharged — but he still 'won't be using his hand for another week or so until the residual swelling and bruising subsides." 'He still loves the Palisades and its wildlife, but he's learned a valuable lesson: admire from a distance," the hospital wrote. "He'll think twice before intervening again, no matter how good his intentions." Read the original article on People
News18
23-05-2025
- Health
- News18
Cyclist's Attempt To Rescue Snake From Being Run Over Ends With Venomous Bite
Last Updated: New York cyclist's good deed goes wrong after he's bitten by a venomous copperhead snake while trying to move it off a road. News18 A New York-based cyclist was bitten by a venomous snake after he tried to save it from being run over by traffic, leading to a hospital visit and a badly swollen finger. Dan Geiger, a Manhattan-based writer, was cycling along the Palisades Cliffs in New Jersey when he spotted what looked like a lethargic copperhead snake lying across the road. Fearing it would be crushed by a passing vehicle, he attempted to gently nudge it off the path. But the rescue attempt backfired. 'I just sort of nudged again, and I was just too close," Geiger told local broadcaster Fox5, describing how the snake struck him on the finger with 'precision and speed." Officials at the Hackensack University Medical Center, where he was treated, said Geiger's finger turned deep purple and swelled alarmingly. Two passersby helped him call emergency services and he was rushed to hospital, where doctors administered antivenom to stop the venom from spreading further. Doctors say while antivenom halts the worsening of symptoms, it does not reverse damage already caused. 'It just stops things from getting worse," said Dr Daria Falkowitz, a medical toxicologist at the hospital, while speaking to the broadcaster. 'It just stops things from getting worse, and so whatever tissue damage has already occurred prior to receiving it, is there. Though initially it doesn't look bad, the damage has been done, so we expect some progression over a day or two," she further added. Geiger spent two nights under observation and has since been discharged, though doctors have advised that he won't be able to use his hand for at least a week. Copperhead snakes are venomous but rarely fatal. They are found in parts of North America, including New Jersey. Experts say such snakes generally avoid human contact, and incidents like this are uncommon. Copperhead snakes, native to parts of the eastern and central US, typically grow between 2 and 3 feet in length. Known for their distinctive copper-colored heads and hourglass-shaped patterns on their bodies, they are among the most commonly encountered venomous snakes in the region. While their bites are rarely fatal, they can cause significant tissue damage and require prompt medical attention. According to data from the US Centers for Disease Control and Prevention (CDC), the United States sees about 7,000 to 8,000 venomous snake bites annually, with an average of five fatalities each year First Published: May 24, 2025, 00:00 IST
